2025 American Society of Clinical Oncology Annual Meeting
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will feature key research and treatment updates in thoracic oncology. The annual meeting provides opportunities to “discover state-of-the-art research, groundbreaking treatments, and visionary insights that will ignite your passion for oncology,” organizers said. The 2025 ASCO Annual Meeting is taking place May 30 to June 3, 2025, in Chicago, Illinois.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.